JP2009523154A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2009523154A5 JP2009523154A5 JP2008549873A JP2008549873A JP2009523154A5 JP 2009523154 A5 JP2009523154 A5 JP 2009523154A5 JP 2008549873 A JP2008549873 A JP 2008549873A JP 2008549873 A JP2008549873 A JP 2008549873A JP 2009523154 A5 JP2009523154 A5 JP 2009523154A5
- Authority
- JP
- Japan
- Prior art keywords
- antibody
- asthma
- seq
- antigen
- binding fragment
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 208000006673 asthma Diseases 0.000 claims 24
- 239000012634 fragment Substances 0.000 claims 22
- 239000000427 antigen Substances 0.000 claims 19
- 102000036639 antigens Human genes 0.000 claims 19
- 108091007433 antigens Proteins 0.000 claims 19
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 15
- 210000004027 cell Anatomy 0.000 claims 11
- 201000010099 disease Diseases 0.000 claims 9
- 208000035475 disorder Diseases 0.000 claims 6
- 150000003431 steroids Chemical class 0.000 claims 6
- 229950011485 pascolizumab Drugs 0.000 claims 5
- 238000004519 manufacturing process Methods 0.000 claims 4
- 208000009657 Aspirin-Induced Asthma Diseases 0.000 claims 3
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 claims 3
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims 3
- 208000011231 Crohn disease Diseases 0.000 claims 3
- 206010012438 Dermatitis atopic Diseases 0.000 claims 3
- 208000017604 Hodgkin disease Diseases 0.000 claims 3
- 208000010747 Hodgkins lymphoma Diseases 0.000 claims 3
- 201000009794 Idiopathic Pulmonary Fibrosis Diseases 0.000 claims 3
- 208000004554 Leishmaniasis Diseases 0.000 claims 3
- 208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 claims 3
- 206010039085 Rhinitis allergic Diseases 0.000 claims 3
- 208000034189 Sclerosis Diseases 0.000 claims 3
- 201000009961 allergic asthma Diseases 0.000 claims 3
- 201000010105 allergic rhinitis Diseases 0.000 claims 3
- 125000000539 amino acid group Chemical group 0.000 claims 3
- 201000008937 atopic dermatitis Diseases 0.000 claims 3
- 208000029771 childhood onset asthma Diseases 0.000 claims 3
- 208000032852 chronic lymphocytic leukemia Diseases 0.000 claims 3
- 208000019425 cirrhosis of liver Diseases 0.000 claims 3
- 230000001419 dependent effect Effects 0.000 claims 3
- 239000003814 drug Substances 0.000 claims 3
- 239000003937 drug carrier Substances 0.000 claims 3
- 230000003176 fibrotic effect Effects 0.000 claims 3
- 238000005469 granulation Methods 0.000 claims 3
- 230000003179 granulation Effects 0.000 claims 3
- 208000036971 interstitial lung disease 2 Diseases 0.000 claims 3
- 210000004185 liver Anatomy 0.000 claims 3
- 238000000034 method Methods 0.000 claims 3
- 208000024696 nocturnal asthma Diseases 0.000 claims 3
- 239000008194 pharmaceutical composition Substances 0.000 claims 3
- 230000000750 progressive effect Effects 0.000 claims 3
- 230000022983 regulation of cell cycle Effects 0.000 claims 3
- 201000004409 schistosomiasis Diseases 0.000 claims 3
- 230000009885 systemic effect Effects 0.000 claims 3
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 2
- 101001076430 Homo sapiens Interleukin-13 Proteins 0.000 claims 2
- 102000019207 human interleukin-13 Human genes 0.000 claims 2
- 239000002609 medium Substances 0.000 claims 2
- 102000040430 polynucleotide Human genes 0.000 claims 2
- 108091033319 polynucleotide Proteins 0.000 claims 2
- 239000002157 polynucleotide Substances 0.000 claims 2
- 241000282693 Cercopithecidae Species 0.000 claims 1
- 241000282567 Macaca fascicularis Species 0.000 claims 1
- 241000288906 Primates Species 0.000 claims 1
- 150000001413 amino acids Chemical class 0.000 claims 1
- 230000010056 antibody-dependent cellular cytotoxicity Effects 0.000 claims 1
- 210000004978 chinese hamster ovary cell Anatomy 0.000 claims 1
- 230000024203 complement activation Effects 0.000 claims 1
- 210000003527 eukaryotic cell Anatomy 0.000 claims 1
- 210000004962 mammalian cell Anatomy 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 102000004196 processed proteins & peptides Human genes 0.000 claims 1
- 108090000765 processed proteins & peptides Proteins 0.000 claims 1
- 239000012679 serum free medium Substances 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB0600488.1A GB0600488D0 (en) | 2006-01-11 | 2006-01-11 | Immunoglobulins |
| PCT/EP2007/050219 WO2007080174A2 (en) | 2006-01-11 | 2007-01-10 | Chimeric and humanised anti-human il-13 antibodies |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2009523154A JP2009523154A (ja) | 2009-06-18 |
| JP2009523154A5 true JP2009523154A5 (enExample) | 2010-02-18 |
Family
ID=35997844
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2008549873A Pending JP2009523154A (ja) | 2006-01-11 | 2007-01-10 | キメラおよびヒト化抗ヒトｉｌ−１３抗体 |
Country Status (18)
| Country | Link |
|---|---|
| EP (1) | EP1976881A2 (enExample) |
| JP (1) | JP2009523154A (enExample) |
| KR (1) | KR20080113201A (enExample) |
| CN (1) | CN101370829A (enExample) |
| AR (1) | AR058955A1 (enExample) |
| AU (1) | AU2007204372A1 (enExample) |
| BR (1) | BRPI0706481A2 (enExample) |
| CA (1) | CA2635972A1 (enExample) |
| CR (1) | CR10161A (enExample) |
| EA (1) | EA200801520A1 (enExample) |
| GB (1) | GB0600488D0 (enExample) |
| IL (1) | IL192207A0 (enExample) |
| MA (1) | MA30156B1 (enExample) |
| NO (1) | NO20082767L (enExample) |
| PE (1) | PE20081185A1 (enExample) |
| TW (1) | TW200736274A (enExample) |
| WO (1) | WO2007080174A2 (enExample) |
| ZA (1) | ZA200805526B (enExample) |
Families Citing this family (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MY144906A (en) | 2005-10-21 | 2011-11-30 | Novartis Ag | Human antibodies against il13 and therapeutic uses |
| TWI422387B (zh) | 2006-05-25 | 2014-01-11 | Glaxo Group Ltd | 免疫球蛋白 |
| EP2050764A1 (en) * | 2007-10-15 | 2009-04-22 | sanofi-aventis | Novel polyvalent bispecific antibody format and uses thereof |
| EP2358754A1 (en) * | 2008-11-26 | 2011-08-24 | Glaxo Group Limited | Ligands that bind il-13 |
| PE20160653A1 (es) * | 2009-03-05 | 2016-07-24 | Abbvie Inc | Proteinas de union a il-17 |
| GB0904214D0 (en) | 2009-03-11 | 2009-04-22 | Ucb Pharma Sa | Biological products |
| EA201190275A1 (ru) * | 2009-05-28 | 2012-11-30 | Глаксо Груп Лимитед | Белок, связывающий интерлейкин-13 (il-13) |
| PL3037104T3 (pl) | 2009-10-20 | 2020-11-16 | Abbvie Inc. | Izolacja i oczyszczanie przeciwciał anty-il-13 z zastosowaniem chromatografii powinowactwa z białkiem a |
| JP2013544235A (ja) * | 2010-10-15 | 2013-12-12 | メドイミューン・リミテッド | 肺機能を改善する治療法 |
| KR101615474B1 (ko) | 2010-12-16 | 2016-04-25 | 제넨테크, 인크. | Th2 억제에 관한 진단 및 치료 |
| EP2686014A1 (en) | 2011-03-16 | 2014-01-22 | Sanofi | Uses of a dual v region antibody-like protein |
| AR098155A1 (es) | 2013-10-23 | 2016-05-04 | Genentech Inc | Métodos para diagnosticar y tratar trastornos eosinofílicos |
| JP2017507939A (ja) | 2014-02-21 | 2017-03-23 | ジェネンテック， インコーポレイテッド | 抗ｉｌ−１３／ｉｌ−１７二重特異性抗体及びその使用 |
| CN106536754B (zh) | 2014-04-11 | 2021-04-16 | 诺华股份有限公司 | 用il-13拮抗剂选择性治疗哮喘的方法 |
| CN107430117A (zh) | 2015-03-16 | 2017-12-01 | 豪夫迈·罗氏有限公司 | 检测和定量IL‑13的方法和在诊断和治疗Th2相关疾病中的用途 |
| EP3433615A1 (en) | 2016-03-21 | 2019-01-30 | Institut National de la Sante et de la Recherche Medicale (INSERM) | Methods for diagnosis and treatment of solar lentigo |
| WO2017189805A1 (en) | 2016-04-27 | 2017-11-02 | Abbvie Inc. | Methods of treatment of diseases in which il-13 activity is detrimental using anti-il-13 antibodies |
| EP3572426A4 (en) * | 2017-01-23 | 2020-12-23 | Toyo University | ANTI-BODY ANTI-EPHA2 AND IMMUNOLOGICAL DETECTION OF EPHA2 CALLING ANTI-BODY AUDIT |
| CN109776677B (zh) * | 2017-11-15 | 2023-11-03 | 尚华科创投资管理（江苏）有限公司 | 一种人源化抗il-13抗体及其制备方法和应用 |
| CN107909501B (zh) * | 2017-12-05 | 2020-12-01 | 创新先进技术有限公司 | 气味与行为的关联方法、气味社交方法及装置 |
| PE20211304A1 (es) | 2018-02-09 | 2021-07-20 | Genentech Inc | Metodos terapeuticos y diagnosticos para enfermedades inflamatorias mediadas por mastocitos |
| WO2020092015A1 (en) | 2018-11-02 | 2020-05-07 | University Of Rochester | Therapeutic mitigation of epithelial infection |
| JP2022525703A (ja) * | 2019-03-20 | 2022-05-18 | ジャベリン・オンコロジー・インコーポレイテッド | 抗ａｄａｍ１２抗体およびキメラ抗原受容体、ならびにそれを含む組成物および方法 |
| GB201919062D0 (en) * | 2019-12-20 | 2020-02-05 | Ucb Biopharma Sprl | Antibody |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2006503018A (ja) * | 2002-08-30 | 2006-01-26 | グラクソ グループ リミテッド | ワクチン |
| WO2004096849A2 (en) * | 2003-04-25 | 2004-11-11 | University Of Manitoba | Peptide-based cytokine/chemokine vaccines against allergy |
| PL1711528T3 (pl) * | 2003-12-23 | 2012-11-30 | Genentech Inc | Leczenie nowotworu nowymi przeciwciałami monoklonalnymi anty-IL13 |
| US7501121B2 (en) * | 2004-06-17 | 2009-03-10 | Wyeth | IL-13 binding agents |
| TWI307630B (en) * | 2004-07-01 | 2009-03-21 | Glaxo Group Ltd | Immunoglobulins |
-
2006
- 2006-01-11 GB GBGB0600488.1A patent/GB0600488D0/en not_active Ceased
-
2007
- 2007-01-09 TW TW096100833A patent/TW200736274A/zh unknown
- 2007-01-09 PE PE2007000018A patent/PE20081185A1/es not_active Application Discontinuation
- 2007-01-09 AR ARP070100082A patent/AR058955A1/es unknown
- 2007-01-10 EA EA200801520A patent/EA200801520A1/ru unknown
- 2007-01-10 CN CNA2007800022973A patent/CN101370829A/zh active Pending
- 2007-01-10 JP JP2008549873A patent/JP2009523154A/ja active Pending
- 2007-01-10 BR BRPI0706481-0A patent/BRPI0706481A2/pt not_active IP Right Cessation
- 2007-01-10 WO PCT/EP2007/050219 patent/WO2007080174A2/en not_active Ceased
- 2007-01-10 CA CA002635972A patent/CA2635972A1/en not_active Abandoned
- 2007-01-10 KR KR1020087019555A patent/KR20080113201A/ko not_active Withdrawn
- 2007-01-10 AU AU2007204372A patent/AU2007204372A1/en not_active Abandoned
- 2007-01-10 EP EP07703766A patent/EP1976881A2/en not_active Withdrawn
-
2008
- 2008-06-16 IL IL192207A patent/IL192207A0/en unknown
- 2008-06-16 NO NO20082767A patent/NO20082767L/no not_active Application Discontinuation
- 2008-06-24 ZA ZA200805526A patent/ZA200805526B/xx unknown
- 2008-07-11 MA MA31108A patent/MA30156B1/fr unknown
- 2008-07-17 CR CR10161A patent/CR10161A/es not_active Application Discontinuation
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2009523154A5 (enExample) | ||
| HRP20120139T1 (hr) | Kimerna i humanizirana monoklonska protutijela protiv interleukina 13 | |
| JP2008511542A5 (enExample) | ||
| CN108367075B (zh) | 4-1bb结合蛋白及其用途 | |
| JP2022075818A5 (enExample) | ||
| CN104774266B (zh) | 白介素-13结合蛋白 | |
| JP2020079252A5 (enExample) | ||
| JP2010534478A5 (enExample) | ||
| JP2020517249A5 (enExample) | ||
| JP2009519718A5 (enExample) | ||
| IL207618A (en) | Bio-specific antibodies that inhibit pdgfr beta and a-vegf, preparations, their uses and methods for their production | |
| RU2018137811A (ru) | Антитела против il-33, композиции, способы и их применение | |
| RU2013110874A (ru) | Антитела против il-18r1 и их применения | |
| JP2023134618A5 (enExample) | ||
| RU2017134495A (ru) | Антитела к альфа-рецептору собачьего интерлейкина-4 | |
| CA2853357A1 (en) | Immunobinders directed against tnf | |
| RU2010149746A (ru) | Перекрестно-реактивные антитела анти-il-17a/il-17f и способы их применения | |
| HRP20191697T1 (hr) | Vezujuće molekule za bcma i cd3 | |
| JP2018500883A5 (enExample) | ||
| JP2012525829A5 (enExample) | ||
| JP2009537608A5 (enExample) | ||
| JP2010524435A5 (enExample) | ||
| JP2007530068A5 (enExample) | ||
| JP2020518248A5 (enExample) | ||
| JP2019516392A5 (enExample) |